Petros Pharmaceuticals, Inc. (PTPI)
Petros Pharmaceuticals, Inc. is a pharmaceutical company dedicated to male health solutions. Their activities include both the commercialization and ongoing development of Stendra, a prescription PDE-5 inhibitor specifically designed for treating erectile dysfunction (ED). Furthermore, Petros is advancing H100, a proprietary topical formulation currently in development as a potential treatment for acute Peyronie's disease. The company's offerings also extend to a range of erectile dysfunction products, such as vacuum erection devices. Petros Pharmaceuticals, Inc. operates from its base in New York, New York.
Sector: Pharmaceutical Preparations
Industry: Drug Manufacturers - Specialty & Generic
Petros Pharmaceuticals, Inc.
Petros Pharmaceuticals, Inc. (PTPI) dilution facts from SEC filings
Snapshot as of Jun 30, 2026, built from 31 SEC filings.
- At-the-market (ATM) program
- No active program in the filings reviewed
- Warrants outstanding
- 3 warrant series recorded as outstanding
- Most recent offering
- None recorded in the filings reviewed
Check another stock for dilution
Facts as recorded in the company's SEC filings. The full snapshot, with instrument terms, share counts and history, is part of Signal8 Pro.